- Home
- SPHL vs SNGX Comparison
SPHL vs SNGX Comparison
Compare SPHL & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHL
- SNGX
- Stock Information
- Founded
- SPHL 2002
- SNGX 1987
- Country
- SPHL Singapore
- SNGX United States
- Employees
- SPHL N/A
- SNGX N/A
- Industry
- SPHL Homebuilding
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- SPHL Consumer Discretionary
- SNGX Health Care
- Exchange
- SPHL Nasdaq
- SNGX Nasdaq
- Market Cap
- SPHL 5.7M
- SNGX 6.5M
- IPO Year
- SPHL 2024
- SNGX 1987
- Fundamental
- Price
- SPHL $0.60
- SNGX $1.86
- Analyst Decision
- SPHL
- SNGX
- Analyst Count
- SPHL 0
- SNGX 0
- Target Price
- SPHL N/A
- SNGX N/A
- AVG Volume (30 Days)
- SPHL 1.5M
- SNGX 26.0K
- Earning Date
- SPHL 02-21-2025
- SNGX 05-09-2025
- Dividend Yield
- SPHL N/A
- SNGX N/A
- EPS Growth
- SPHL N/A
- SNGX N/A
- EPS
- SPHL N/A
- SNGX N/A
- Revenue
- SPHL $6,456,601.00
- SNGX $2,342.00
- Revenue This Year
- SPHL N/A
- SNGX N/A
- Revenue Next Year
- SPHL N/A
- SNGX N/A
- P/E Ratio
- SPHL N/A
- SNGX N/A
- Revenue Growth
- SPHL N/A
- SNGX N/A
- 52 Week Low
- SPHL $0.35
- SNGX $1.68
- 52 Week High
- SPHL $7.80
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- SPHL N/A
- SNGX 38.46
- Support Level
- SPHL N/A
- SNGX $1.83
- Resistance Level
- SPHL N/A
- SNGX $2.00
- Average True Range (ATR)
- SPHL 0.00
- SNGX 0.10
- MACD
- SPHL 0.00
- SNGX -0.00
- Stochastic Oscillator
- SPHL 0.00
- SNGX 11.11
About SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).